Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTIER 4 long-term open-label study of Mim8 in hemophilia A with or without inhibitors
CTR20241109Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started May 2024; status: active.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20241109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241109.